Evidence map›Paper›PMID 34067451›Full record

ArticlePharmaceutics2021

Translational Studies on the Potential of a VEGF Nanoparticle-Loaded Hyaluronic Acid Hydrogel.

Joanne O'Dwyer, Robert Murphy, Arlyng González-Vázquez, Lenka Kovarova, Martin Pravda, Vladimir Velebny, Andreas Heise, Garry P Duffy, Sally Ann Cryan

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Lymphangiogenesis: A new strategy for heart disease treatment (Review).International journal of molecular medicine · 2024
    Review
  5. Review
  6. Review
  7. Article
  8. Engineering Spatiotemporal Control in Vascularized Tissues.Bioengineering (Basel, Switzerland) · 2022
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Joanne O'DwyerDrug Delivery & Advanced Materials Team, School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland.
Robert MurphyDepartment of Chemistry, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland.
Arlyng González-VázquezTissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland.ORCID 0000-0003-0648-5590
Lenka KovarovaR&D Department, Contipro, Dolni Dobrouc 401, 561 02 Dolni Dobrouc, Czech Republic.
Martin PravdaR&D Department, Contipro, Dolni Dobrouc 401, 561 02 Dolni Dobrouc, Czech Republic.
Vladimir VelebnyR&D Department, Contipro, Dolni Dobrouc 401, 561 02 Dolni Dobrouc, Czech Republic.
Andreas HeiseDepartment of Chemistry, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland.ORCID 0000-0001-5916-8500
Garry P DuffyTissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland.
Sally Ann CryanDrug Delivery & Advanced Materials Team, School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland.
Royal College of Surgeons in Ireland · IEContipro (Czechia) · CZ

Funding

Science Foundation Ireland 13/IA/1840Seventh Framework Programme 604531
6 · The paper itself

Abstract

Heart failure has a five-year mortality rate approaching 50%. Inducing angiogenesis following a myocardial infarction is hypothesized to reduce cardiomyocyte death and tissue damage, thereby preventing heart failure. Herein, a novel nano-in-gel delivery system for vascular endothelial growth factor (VEGF), composed of star-shaped polyglutamic acid-VEGF nanoparticles in a tyramine-modified hyaluronic acid hydrogel (nano-VEGF-HA-TA), is investigated. The ability of the nano-VEGF-HA-TA system to induce angiogenesis is assessed in vivo using a chick chorioallantoic membrane model (CAM). The formulation is then integrated with a custom-made, clinically relevant catheter suitable for minimally invasive endocardial delivery and the effect of injection on hydrogel properties is examined. Nano-VEGF-HA-TA is biocompatible on a CAM assay and significantly improves blood vessel branching (

Indexed as

angiogenic growth factorcatheter deliverychick chorioallantoic membrane modelhyaluronic acid hydrogelnanoparticle-loaded hydrogelprotein deliverysustained releasevascular endothelial growth factor nanoparticles

Identifiers

PMID34067451
PMCPMC8224549
OpenAlexW3165516131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.